This site is intended for health professionals only

Warning on trastuzumab heart risks

teaser

Adjuvant trastuzumab provides substantial benefits to patients with human epidermal growth factor receptor 2 positive breast cancer, but competing immediate and long-term cardiovascular risks are a great concern, so continued cardiac follow-up of these women is of critical importance.

Such are the conclusions of a paper published in the Journal of Clinical Oncology.

The research assessed the spectrum and reversibility of cardiotoxicity observed in the following adjuvant trastuzumab trials:

• National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31.

• North Central Cancer Treatment Group N9831.

• Herceptin Adjuvant Breast Cancer International Research Group 006.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

• Finland Herceptin trials.

The following findings were reported:

• Up to 4% of patients enrolled in the adjuvant trials experienced severe congestive heart failure during treatment.

• Early-stopping rules in the trials that identified an unacceptable level of cardiotoxicity were never reached, but despite this a large number of patients on these trials experienced some form of cardiotoxicity that ultimately required discontinuation of trastuzumab.

• Some 14% of patients in the NSABP B-31 trial discontinued trastuzumab because of asymptomatic decreases in left ventricular ejection fraction (LVEF).

• Results of follow-up cardiac evaluations of patients diagnosed with any degree of cardiotoxicity in the NSABP B-31 trial document that a clinically significant proportion of patients have sustained decreases in their LVEF to <50%.

J Clin Oncol 2007;25:3525-33

 






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x